Management and outcomes of patients with cancer treated with LMWH adjusted by anti-Xa levels
| Manuscript . | Patients with cancer (n, %) . | Medication . | Therapeutic range . | Reason for monitoring . | Recurrent thrombosis . | Bleeding . |
|---|---|---|---|---|---|---|
| Alhenc-Gelas et al6 | 4/64 (6%) | Dalteparin | 0.5-1 IU/mL | Randomization | 2/64 (3%) | 3/64 minor (5%) |
| Busby et al11 | 1/1 (100%) | Enoxaparin | 0.5-1.1 IU/mL | Bleeding | 0/0 (0%) | 0/0 (0%) |
| Cunningham et al9 | 1/1 (100%) | Enoxaparin | 1 IU/mL | Recurrent thrombosis | 0/0 (0%) | 0/0 (0%) |
| Krajewski et al10 | 1/1 (100%) | Enoxaparin | 0.5-1 IU/mL | Heparin Resistance | 0/0 (0%) | 0/0 (0%) |
| Manuscript . | Patients with cancer (n, %) . | Medication . | Therapeutic range . | Reason for monitoring . | Recurrent thrombosis . | Bleeding . |
|---|---|---|---|---|---|---|
| Alhenc-Gelas et al6 | 4/64 (6%) | Dalteparin | 0.5-1 IU/mL | Randomization | 2/64 (3%) | 3/64 minor (5%) |
| Busby et al11 | 1/1 (100%) | Enoxaparin | 0.5-1.1 IU/mL | Bleeding | 0/0 (0%) | 0/0 (0%) |
| Cunningham et al9 | 1/1 (100%) | Enoxaparin | 1 IU/mL | Recurrent thrombosis | 0/0 (0%) | 0/0 (0%) |
| Krajewski et al10 | 1/1 (100%) | Enoxaparin | 0.5-1 IU/mL | Heparin Resistance | 0/0 (0%) | 0/0 (0%) |